VJHemOnc Podcast

Catherine Bollard and Jeremy Abramson discuss T-cell therapies for NHL, including CAR-T therapies and third-party EBV T-cells. They explore real-world data on CD19-directed CAR-Ts and the potential of CD30, CD20, and CD5-directed CAR-Ts in T-cell lymphomas. Topics include safety and efficacy comparisons of different therapies, prescribing patterns, advancements in T-cell therapies, overcoming challenges in CAR-T development, and targeting antigens beyond CD19.

Experts Nitin Jain and Catherine Coombs discuss key updates in chronic lymphocytic leukemia (CLL), including the changing role of chemotherapy, the promise of next-generation BTK inhibitors, and the options available for frontline therapy. They also explore the use of PITO-Bruhneb in difficult-to-treat populations with CLL and Richter's syndrome.

Experts discuss the evolving treatment landscape in ALL and the role of immunotherapies like ADCs and CAR-T cells. They highlight the potential of targeted therapy and stopping therapy in pH positive ALL. The efficacy of cartizo for CNS infiltration and combination therapy for non-CNS EMD is discussed. The use of immunotherapies in ALL treatment is explored, including the benefits of combining therapies and optimizing immunotherapy. The effects of treatments on the immune system and tumor microenvironment in ALL are examined, including Punatine's impact on T-cells and NK-cells and the potential of LCK inhibition.

Laura Pasqualucci, MD, specializes in R/R follicular lymphoma. Topics include optimal management, combining therapies, sequencing therapies, and role of epigenetic alterations. Explore potential of epigenetic and immunotherapies, CD47 engagement/blocking, and EZH2 inhibition. Also discuss CD58 expression, antigen presentation, and challenges in treating follicular lymphoma.

Experts Richard Stone and David Sallman discuss novel targets, combinations, and treatment strategies in AML. They explore the potential of drugs Eptenoprop and Magrolumab for TP53-mutated AML, and the importance of mature data sets and specific population focus in phase three trials. The use of complete remission rate as a primary endpoint for TP53 mutant patients is questioned, and CD47 inhibition as a potential therapy is explored.

Experts Jorge Cortes and Mhairi Copland discuss recent updates in chronic myeloid leukemia (CML), including treatment strategies for refractory disease, novel agents, and clinical trial updates from the OPTIC and ASCEMBL trials. They highlight the use of new drugs and optimized doses, personalized approaches, and the potential of combining TKI therapy with immunological approaches for improved responses in CML patients.

Experts at iwNHL discuss the importance of understanding the immune microenvironment in NHL, strategies to engage the anti-tumor immune response, and enhancing the efficacy of immune therapies. They explore opportunities for intervention in lymphoma treatment, challenges of engineering complex CARs, and the impact of chemotherapy on the tumor microenvironment.

Robin Foà and Rob Pieters discuss novel treatment strategies in ALL, including the use of Panatinib and TKI options, impact of novel treatments, effectiveness of asparaginase, chemo-free strategies, targeted agents, low-dose chemotherapy, and molecular testing as treatment strategies for ALL.

Leading expert Rafael Bejar and others discuss the role of the innate immune system in MDS, chronic inflammation, its connection to clonal hematopoiesis, aging, and autoimmunity. They delve into abnormal stem cells, toll-like receptors, inflammasome pathways, potential targets for disease-modifying therapies, and cell death in different types of MDS.

Mark Levis, A leading expert in AML research and treatment, discusses the standard of care in AML in 2022, including the role of transplantation and novel agents and treatment approaches for relapsed FLT3-mutated disease. Transplant benefits and considerations, BMTCTN trial analysis, and treatment considerations based on age and fitness level are also discussed. Stem cell transplants and targeted therapies are explored, emphasizing the importance of collaboration between leukemia and transplant physicians.